A prospectively validated translational meta-model framework for in silico prediction of dose-ranging Phase 2B tuberculosis regimen outcomes

Over two-thirds of drug candidates fail during mid-stage clinical development primarily due to insufficient efficacy. This challenge is particularly acute in tuberculosis, where new drugs must be evaluated in combination regimens at appropriate doses, and promising earlier findings have not consistently translated into conclusive Phase 2 results. Here we present a translational meta-model framework for quantitative prediction of dose-ranging Phase 2B tuberculosis regimen outcomes that integrates preclinical pharmacology with historically informed patient heterogeneity. We developed the methodology by back-translating four historical trials, followed by prospective validation through blinded predictions in a first-in-patient Phase 2 trial. Updating only drug-specific preclinical data, the validated framework predicts dose-response and performance versus control for novel regimens, with a quantitative efficacy benchmark further informing their treatment-shortening potential. Our platform enables rational regimen design and dose selection 3–4 years before clinical evaluation, de-risking mid-stage tuberculosis drug development, with potential for extension to other diseases.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-19
DOI
https://doi.org/10.21203/rs.3.rs-11778751/v1
Primary Topic
Statistical Methods in Clinical Trials
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

A prospectively validated translational meta-model framework for in silico prediction of dose-ranging Phase 2B tuberculosis regimen outcomes

Eunsol Yang, Eric L. Nuermberger, Rob Christiaan van Wijk, Siyang Li et al.
Research Square
Statistical Methods in Clinical Trials
preprint

A prospectively validated translational meta-model framework for in silico prediction of dose-ranging Phase 2B tuberculosis regimen outcomes

Eunsol Yang, Eric L. Nuermberger, Rob Christiaan van Wijk, Siyang Li, Niurys de Castro Suarez, Anu Patel, Connie Silva, Rada M. Savic, Sejung Hwang
preprint en

Abstract

Over two-thirds of drug candidates fail during mid-stage clinical development primarily due to insufficient efficacy. This challenge is particularly acute in tuberculosis, where new drugs must be evaluated in combination regimens at appropriate doses, and promising earlier findings have not consistently translated into conclusive Phase 2 results. Here we present a translational meta-model framework for quantitative prediction of dose-ranging Phase 2B tuberculosis regimen outcomes that integrates preclinical pharmacology with historically informed patient heterogeneity. We developed the methodology by back-translating four historical trials, followed by prospective validation through blinded predictions in a first-in-patient Phase 2 trial. Updating only drug-specific preclinical data, the validated framework predicts dose-response and performance versus control for novel regimens, with a quantitative efficacy benchmark further informing their treatment-shortening potential. Our platform enables rational regimen design and dose selection 3–4 years before clinical evaluation, de-risking mid-stage tuberculosis drug development, with potential for extension to other diseases.

Research Square
Johns Hopkins University (US), University of California, San Francisco (US)
Statistical Methods in Clinical Trials
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon